Exploring the Multifaceted Role of Obesity in Breast Cancer Progression

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2024 Jul 23

PMID 39040042

Authors

Sooraj Kakkat

Prabhat Suman

Elba A Turbat-Herrera

Seema Singh

Debanjan Chakroborty

Chandrani Sarkar

Affiliations

Soon will be listed here.

Abstract

Obesity is a multifaceted metabolic disorder characterized by excessive accumulation of adipose tissue. It is a well-established risk factor for the development and progression of breast cancer. Adipose tissue, which was once regarded solely as a passive energy storage depot, is now acknowledged as an active endocrine organ producing a plethora of bioactive molecules known as adipokines that contribute to the elevation of proinflammatory cytokines and estrogen production due to enhanced aromatase activity. In the context of breast cancer, the crosstalk between adipocytes and cancer cells within the adipose microenvironment exerts profound effects on tumor initiation, progression, and therapeutic resistance. Moreover, adipocytes can engage in direct interactions with breast cancer cells through physical contact and paracrine signaling, thereby facilitating cancer cell survival and invasion. This review endeavors to summarize the current understanding of the intricate interplay between adipocyte-associated factors and breast cancer progression. Furthermore, by discussing the different aspects of breast cancer that can be adversely affected by obesity, this review aims to shed light on potential avenues for new and novel therapeutic interventions.

Citing Articles

Percentage of fat in milk consumption and risk of six cancers: a Mendelian randomization study.

Bai T, Wu C Transl Cancer Res. 2025; 13(12):6613-6622.

PMID: 39816557 PMC: 11730444. DOI: 10.21037/tcr-24-802.

References

Franzen B, Alexeyenko A, Kamali-Moghaddam M, Hatschek T, Kanter L, Ramqvist T . Protein profiling of fine-needle aspirates reveals subtype-associated immune signatures and involvement of chemokines in breast cancer. Mol Oncol. 2018; 13(2):376-391. PMC: 6360506. DOI: 10.1002/1878-0261.12410. View

Gelsomino L, Naimo G, Malivindi R, Augimeri G, Panza S, Giordano C . Knockdown of Leptin Receptor Affects Macrophage Phenotype in the Tumor Microenvironment Inhibiting Breast Cancer Growth and Progression. Cancers (Basel). 2020; 12(8). PMC: 7464041. DOI: 10.3390/cancers12082078. View

Lund S, Giachelli C, Scatena M . The role of osteopontin in inflammatory processes. J Cell Commun Signal. 2009; 3(3-4):311-22. PMC: 2778587. DOI: 10.1007/s12079-009-0068-0. View

Park J, Zhao L, Willingham M, Cheng S . Inhibition of STAT3 signaling blocks obesity-induced mammary hyperplasia in a mouse model. Am J Cancer Res. 2017; 7(3):727-739. PMC: 5385655. View

Park S, Yu Y, Zides C, Beyak M . Mechanisms of reduced leptin-mediated satiety signaling during obesity. Int J Obes (Lond). 2022; 46(6):1212-1221. DOI: 10.1038/s41366-022-01079-2. View

Georgiou G, Provatopoulou X, Kalogera E, Siasos G, Menenakos E, Zografos G . Serum resistin is inversely related to breast cancer risk in premenopausal women. Breast. 2016; 29:163-9. DOI: 10.1016/j.breast.2016.07.025. View

Su Y, Wu Y, Ann D, Chen J, Kuo C . Obesity promotes radioresistance through SERPINE1-mediated aggressiveness and DNA repair of triple-negative breast cancer. Cell Death Dis. 2023; 14(1):53. PMC: 9867751. DOI: 10.1038/s41419-023-05576-8. View

Surmacz E, Burgaud J . Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. Clin Cancer Res. 1995; 1(11):1429-36. View

Kim H, Jung M, Choi S, Woo J, Piao Y, Hwang E . IL-6-mediated cross-talk between human preadipocytes and ductal carcinoma in situ in breast cancer progression. J Exp Clin Cancer Res. 2018; 37(1):200. PMC: 6106749. DOI: 10.1186/s13046-018-0867-3. View

10.

Schwartz D, Lazar M . Human resistin: found in translation from mouse to man. Trends Endocrinol Metab. 2011; 22(7):259-65. PMC: 3130099. DOI: 10.1016/j.tem.2011.03.005. View

11.

Lee M, Wu Y, Fried S . Adipose tissue remodeling in pathophysiology of obesity. Curr Opin Clin Nutr Metab Care. 2010; 13(4):371-6. PMC: 3235038. DOI: 10.1097/MCO.0b013e32833aabef. View

12.

Deshmukh S, Srivastava S, Zubair H, Bhardwaj A, Tyagi N, Al-Ghadhban A . Resistin potentiates chemoresistance and stemness of breast cancer cells: Implications for racially disparate therapeutic outcomes. Cancer Lett. 2017; 396:21-29. PMC: 5437742. DOI: 10.1016/j.canlet.2017.03.010. View

13.

Yee L, Mortimer J, Natarajan R, Dietze E, Seewaldt V . Metabolic Health, Insulin, and Breast Cancer: Why Oncologists Should Care About Insulin. Front Endocrinol (Lausanne). 2020; 11:58. PMC: 7045050. DOI: 10.3389/fendo.2020.00058. View

14.

Teras L, Patel A, Wang M, Yaun S, Anderson K, Brathwaite R . Sustained Weight Loss and Risk of Breast Cancer in Women 50 Years and Older: A Pooled Analysis of Prospective Data. J Natl Cancer Inst. 2019; 112(9):929-937. PMC: 7492760. DOI: 10.1093/jnci/djz226. View

15.

Papanikolaou V, Stefanou N, Dubos S, Papathanasiou I, Palianopoulou M, Valiakou V . Synergy of leptin/STAT3 with HER2 receptor induces tamoxifen resistance in breast cancer cells through regulation of apoptosis-related genes. Cell Oncol (Dordr). 2014; 38(2):155-64. DOI: 10.1007/s13402-014-0213-5. View

16.

Uribesalgo I, Hoffmann D, Zhang Y, Kavirayani A, Lazovic J, Berta J . Apelin inhibition prevents resistance and metastasis associated with anti-angiogenic therapy. EMBO Mol Med. 2019; 11(8):e9266. PMC: 6685079. DOI: 10.15252/emmm.201809266. View

17.

Folkerd E, Dixon J, Renshaw L, AHern R, Dowsett M . Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol. 2012; 30(24):2977-80. DOI: 10.1200/JCO.2012.42.0273. View

18.

Jaberi S, Cohen A, DSouza C, Abdulrazzaq Y, Ojha S, Bastaki S . Lipocalin-2: Structure, function, distribution and role in metabolic disorders. Biomed Pharmacother. 2021; 142:112002. DOI: 10.1016/j.biopha.2021.112002. View

19.

Tulotta C, Ottewell P . The role of IL-1B in breast cancer bone metastasis. Endocr Relat Cancer. 2018; 25(7):R421-R434. PMC: 5987176. DOI: 10.1530/ERC-17-0309. View

20.

Huang J, Wang Y, Lo S, Tseng L, Chen D, Wu Y . Visfatin Mediates Malignant Behaviors through Adipose-Derived Stem Cells Intermediary in Breast Cancer. Cancers (Basel). 2019; 12(1). PMC: 7016886. DOI: 10.3390/cancers12010029. View